These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25186968)

  • 1. Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R.
    Weisberg E; Nonami A; Chen Z; Nelson E; Chen Y; Liu F; Cho H; Zhang J; Sattler M; Mitsiades C; Wong KK; Liu Q; Gray NS; Griffin JD
    Clin Cancer Res; 2014 Nov; 20(21):5483-95. PubMed ID: 25186968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β.
    Bielen A; Perryman L; Box GM; Valenti M; de Haven Brandon A; Martins V; Jury A; Popov S; Gowan S; Jeay S; Raynaud FI; Hofmann F; Hargrave D; Eccles SA; Jones C
    Mol Cancer Ther; 2011 Aug; 10(8):1407-18. PubMed ID: 21659463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IGF-1R inhibition induces MEK phosphorylation to promote survival in colon carcinomas.
    Wang Q; Zhang Y; Zhu J; Zheng H; Chen S; Chen L; Yang HS
    Signal Transduct Target Ther; 2020 Aug; 5(1):153. PubMed ID: 32843616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.
    Flanigan SA; Pitts TM; Newton TP; Kulikowski GN; Tan AC; McManus MC; Spreafico A; Kachaeva MI; Selby HM; Tentler JJ; Eckhardt SG; Leong S
    Clin Cancer Res; 2013 Nov; 19(22):6219-29. PubMed ID: 24045180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.
    Guenther LM; Dharia NV; Ross L; Conway A; Robichaud AL; Catlett JL; Wechsler CS; Frank ES; Goodale A; Church AJ; Tseng YY; Guha R; McKnight CG; Janeway KA; Boehm JS; Mora J; Davis MI; Alexe G; Piccioni F; Stegmaier K
    Clin Cancer Res; 2019 Feb; 25(4):1343-1357. PubMed ID: 30397176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors.
    Tarn C; Rink L; Merkel E; Flieder D; Pathak H; Koumbi D; Testa JR; Eisenberg B; von Mehren M; Godwin AK
    Proc Natl Acad Sci U S A; 2008 Jun; 105(24):8387-92. PubMed ID: 18550829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies.
    Weisberg E; Nonami A; Chen Z; Liu F; Zhang J; Sattler M; Nelson E; Cowens K; Christie AL; Mitsiades C; Wong KK; Liu Q; Gray N; Griffin JD
    Leukemia; 2015 Jan; 29(1):27-37. PubMed ID: 24791855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repression of malignant tumor progression upon pharmacologic IGF1R blockade in a mouse model of insulinoma.
    Zumsteg A; Caviezel C; Pisarsky L; Strittmatter K; García-Echeverría C; Hofmann F; Christofori G
    Mol Cancer Res; 2012 Jun; 10(6):800-9. PubMed ID: 22562956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein.
    Jenkins CE; Shevchuk OO; Giambra V; Lam SH; Carboni JM; Gottardis MM; Holzenberger M; Pollak M; Humphries RK; Weng AP
    Exp Hematol; 2012 Sep; 40(9):715-723.e6. PubMed ID: 22613471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma.
    Abraham J; Prajapati SI; Nishijo K; Schaffer BS; Taniguchi E; Kilcoyne A; McCleish AT; Nelon LD; Giles FG; Efstratiadis A; LeGallo RD; Nowak BM; Rubin BP; Malempati S; Keller C
    Mol Cancer Ther; 2011 Apr; 10(4):697-707. PubMed ID: 21447712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion.
    Tazzari PL; Tabellini G; Bortul R; Papa V; Evangelisti C; Grafone T; Martinelli G; McCubrey JA; Martelli AM
    Leukemia; 2007 May; 21(5):886-96. PubMed ID: 17361225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.
    Martins AS; Mackintosh C; Martín DH; Campos M; Hernández T; Ordóñez JL; de Alava E
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3532-40. PubMed ID: 16740780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling.
    Morgan MA; Dolp O; Reuter CW
    Blood; 2001 Mar; 97(6):1823-34. PubMed ID: 11238126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Esophageal cancer exhibits resistance to a novel IGF-1R inhibitor NVP-AEW541 with maintained RAS-MAPK activity.
    Bao XH; Takaoka M; Hao HF; Wang ZG; Fukazawa T; Yamatsuji T; Sakurama K; Sun DS; Nagasaka T; Fujiwara T; Naomoto Y
    Anticancer Res; 2012 Jul; 32(7):2827-34. PubMed ID: 22753744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant HRAS as novel target for MEK and mTOR inhibitors.
    Kiessling MK; Curioni-Fontecedro A; Samaras P; Atrott K; Cosin-Roger J; Lang S; Scharl M; Rogler G
    Oncotarget; 2015 Dec; 6(39):42183-96. PubMed ID: 26544513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.
    Meng J; Dai B; Fang B; Bekele BN; Bornmann WG; Sun D; Peng Z; Herbst RS; Papadimitrakopoulou V; Minna JD; Peyton M; Roth JA
    PLoS One; 2010 Nov; 5(11):e14124. PubMed ID: 21124782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
    Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G
    Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma.
    Xu L; Qi Y; Xu Y; Lian J; Wang X; Ning G; Wang W; Zhu Y
    Oncotarget; 2016 Jun; 7(24):36235-36246. PubMed ID: 27105537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas.
    Piao W; Wang Y; Adachi Y; Yamamoto H; Li R; Imsumran A; Li H; Maehata T; Ii M; Arimura Y; Lee CT; Shinomura Y; Carbone DP; Imai K
    Mol Cancer Ther; 2008 Jun; 7(6):1483-93. PubMed ID: 18566219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours.
    Höpfner M; Baradari V; Huether A; Schöfl C; Scherübl H
    Endocr Relat Cancer; 2006 Mar; 13(1):135-49. PubMed ID: 16601284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.